Scholarlink

Background <p>Microsatellite stable (MSS) gastric cancer (GC) is largely unresponsive to immunotherapy, presenting a persistent and formidable challenge in the field. Patients with advanced GC and <i>Helicobacter pylori</i> (<i>H. pylori</i>) infection have shown benefits from immunotherapy. However, it remains unreported whether neoadjuvant immunotherapy is beneficial for <i>H. pylori</i>-positive MSS GC patients.</p> Methods <p>This retrospective cohort study analyzed data from GC patients treated at three medical centers in China between January 1, 2014, and July 1, 2024. Patients with gastric adenocarcinoma or adenocarcinoma of the gastroesophageal junction underwent testing for <i>H. pylori</i> infection prior to receiving neoadjuvant therapy.</p> Results <p>In this retrospective analysis, those positive for <i>H. pylori</i> had a higher objective response rate of 63.77% (95% CI, 51.98–74.11%) compared to 47.73% (95% CI, 39.39–56.19%) in <i>H. pylori</i>-negative patients. Pathological complete remission was higher in <i>H. pylori</i>-positive patients at 17.39% (95% CI, 10.24–27.98%) versus 15.91% (95% CI, 10.65–23.10%). Logistic regression analysis revealed a strong correlation between <i>H. pylori</i> positivity and increased objective remission rate (<i>P</i> = 0.031, OR = 1.928, 95% CI 1.06–3.51). In <i>H. pylori</i>-positive MSS GC patients receiving neoadjuvant immunotherapy pCR rates can reach 27.27% (95% CI, 15.07–44.21%), much higher than the 8.33% (95% CI, 2.87–21.82%) in neoadjuvant chemotherapy patients. Survival analysis showed a 3-year OS rate of 74.2% (95% CI, 56.75–86.30%) in the <i>H. pylori</i>-positive group and 64.3% (95% CI, 51.20–75.55%) in the <i>H. pylori</i>-negative group, and the hazard ratio (HR) of these two groups was 0.50 (95% CI, 0.28–0.87; <i>P</i> &lt;.001). Multivariable analysis for OS further showed the survival benefit of <i>H. pylori</i>, with HRs of 0.51 (95% CI, 0.29–0.91; <i>P</i> = 0.02).</p> Conclusions <p><i>H. pylori</i> infection has emerged as a favorable factor for neoadjuvant immunotherapy in MSS GC, underscoring the importance of considering <i>H. pylori</i> status in preoperative treatment strategies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Helicobacter pylori reversing the landscape of neoadjuvant immunotherapy for microsatellite stable gastric cancer: a multicenter cohort study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年4月23日

查看全文
  • Chengyu Hu,
  • Hongming Liu,
  • Bo Hong,
  • Li Wang,
  • Zelai Wu,
  • Weixun Xie,
  • Bixian Luo,
  • Dong Cao,
  • Yuxin Zhong,
  • Yong Liu,
  • Weihua Gong

摘要

Background

Microsatellite stable (MSS) gastric cancer (GC) is largely unresponsive to immunotherapy, presenting a persistent and formidable challenge in the field. Patients with advanced GC and Helicobacter pylori (H. pylori) infection have shown benefits from immunotherapy. However, it remains unreported whether neoadjuvant immunotherapy is beneficial for H. pylori-positive MSS GC patients.

Methods

This retrospective cohort study analyzed data from GC patients treated at three medical centers in China between January 1, 2014, and July 1, 2024. Patients with gastric adenocarcinoma or adenocarcinoma of the gastroesophageal junction underwent testing for H. pylori infection prior to receiving neoadjuvant therapy.

Results

In this retrospective analysis, those positive for H. pylori had a higher objective response rate of 63.77% (95% CI, 51.98–74.11%) compared to 47.73% (95% CI, 39.39–56.19%) in H. pylori-negative patients. Pathological complete remission was higher in H. pylori-positive patients at 17.39% (95% CI, 10.24–27.98%) versus 15.91% (95% CI, 10.65–23.10%). Logistic regression analysis revealed a strong correlation between H. pylori positivity and increased objective remission rate (P = 0.031, OR = 1.928, 95% CI 1.06–3.51). In H. pylori-positive MSS GC patients receiving neoadjuvant immunotherapy pCR rates can reach 27.27% (95% CI, 15.07–44.21%), much higher than the 8.33% (95% CI, 2.87–21.82%) in neoadjuvant chemotherapy patients. Survival analysis showed a 3-year OS rate of 74.2% (95% CI, 56.75–86.30%) in the H. pylori-positive group and 64.3% (95% CI, 51.20–75.55%) in the H. pylori-negative group, and the hazard ratio (HR) of these two groups was 0.50 (95% CI, 0.28–0.87; P <.001). Multivariable analysis for OS further showed the survival benefit of H. pylori, with HRs of 0.51 (95% CI, 0.29–0.91; P = 0.02).

Conclusions

H. pylori infection has emerged as a favorable factor for neoadjuvant immunotherapy in MSS GC, underscoring the importance of considering H. pylori status in preoperative treatment strategies.